CPSR

Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

Gelesis' six-month study of weight loss in adults with overweight or obesity who have prediabetes or type 2 diabetes met both of its primary endpoints: the proportion of participants who achieved at least 5% body weight loss (i.e., "Categorical") and the change in body weight after six months of therapy GS200 demonstrated a highly favorable Categorial weight loss response and tolerability in a population that often struggles to lose weight and is at high risk for obesity-related complications; the overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the placebo group ~6 out of 10 GS200-treated adults achieved at least 5% weight loss ("Responders"), losing

New preclinical data presented today at the World of Microbiome Conference suggest adding superabsorbent hydrogel to a high-fat "western-like" diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company announced that its Founded Entity, Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis), released today a poster prPesentation at the World of Microbiome annual meeting in Vienna. The preclinical study showed administration of one of Gelesis' proprietary superabsorbent hydrogels, Gel-B, significantly shifted the composition of the m

Strong capital base with PureTech level cash and cash equivalents of $418.9 million1 and consolidated cash and cash equivalents of $465.7 million2 as of December 31, 2021 Rapidly progressing pipeline of 27 therapeutics and therapeutic candidates, across Wholly Owned and Founded Entity programs, with 11 clinical trials initiated and 6 clinical trial readouts in 2021 Founded Entities continuing to mature and generate value for PureTech, with three now publicly traded and a fourth soon expected to go public Reviewing capital allocation strategy to drive additional value to shareholders with potential returns of capital through various mechanisms Company to host a webcast and conference cal

4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

25-NSE - GELESIS HOLDINGS, INC. (0001805087) (Subject)

PureTech Health plc (NASDAQ:PRTC) founded entity Gelesis Inc, maker of weight management aid, has completed its business combination with Capstar Special Purpose Acquisition Corp (NYSE:CPSR).  The publicly-traded company will be Gelesis Holdings Inc and will begin trading on the New York Stock Exchange under the ticker symbol "GLS" from today. Both Gelesis and Capstar shareholders voted to approve the business combination. The transaction generated approximately $105 million in gross proceeds, which will be mainly used to support the broad launch of Plenity. Related: FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know. "We are pleased with the

Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as "GLS" on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted today that its Founded Entity, Gelesis, Inc. ("Gelesis"), the maker of Plenity®, an FDA-cleared weight management approach, announced the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) ("Capstar"). The publicly traded company will be known as Gelesis Holdings, Inc. and will beg

Proceeds from this transaction will be used to further support the national launch of Plenity Gelesis will begin trading on the New York Stock Exchange as "GLS" on Friday, January 14, 2022 and will ring the opening bell on Tuesday, January 18 Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, announced today the completion of its business combination with Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) ("Capstar"). The publicly traded company will be known as Gelesis Holdings, Inc. ("Gelesis" or "the Company") and will commence trading on the New York Stock Exchange under the ticker symbol "GLS" on January 14, 2022. Both Gelesis Inc. and Capstar shareholders

8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

Gainers Splash Beverage Group, Inc. (NYSE:SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT performance drink in Walmart stores across Florida metropolitan areas. Nutriband Inc. (NASDAQ:NTRB) shares surged 34.9% to settle at $8.15 on Tuesday. Nutriband and Kindeva Drug Delivery, on Monday, signed a feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch. Virgin Orbit Holdings, Inc. (NASDAQ:VORB) gained 31.3% to close at $10.57 on above-average volume Tuesday. Virgin Orbit announced via Twitter Monday that the company is still on track to hit the launch window for its third commercia

Gainers TSR, Inc. (NASDAQ:TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year. Accolade, Inc. (NASDAQ:ACCD) gained 27.3% to $24.36 after the company reported Q3 earnings results and raised FY22 sales guidance. Nuverra Environmental Solutions, Inc. (NYSE:NES) shares jumped 22.6% to $2.8450. BARK, Inc. (NYSE:BARK) gained 18% to $4.25. The company said it expects Q3 sales of $140 million, versus analysts’ estimates of $137.3 million. BARK co-founder and executive chairman Matt Meeker will cecome CEO. Nutriband Inc. (NASDAQ:NTRB) jumped 17.2% to $7.08. Nutriband and Kindeva Drug Delivery, on Mo

Stocks that Broke Yearly Lows Tuesday Morning During Tuesday's morning trading, 87 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Highs And Lows: 10x Genomics (NASDAQ:TXG) was the biggest company on a market cap basis to set a new 52-week low. Siyata Mobile (NASDAQ:SYTA) was the smallest firm on a market cap basis to set a new 52-week low. Capstar Special Purpose (NYSE:CPSR) was the biggest loser, trading down 23.1% to reach its 52-week low. Asia Pacific Wire & Cable (NASDAQ:APWC) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. Stocks that set new 52-week lows during the first half-hour of trading on Tuesday are as fo

Gainers Bone Biologics Corporation (NASDAQ:BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ:ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired by Take-Two Interactive Software in a cash and stock transaction valued at $9.86 per Zynga share, representing a total enterprise value of approximately $12.7 billion. Apria, Inc. (NASDAQ:APR) shares climbed 25.1% to $37.17. Owens & Minor agreed to acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. Pluristem Therapeutics Inc. (NASDAQ:PSTI) gained 22.5% to $1.80. Pluristem Therapeutics and Tnuva Group have collaborated to develop, manufacture a

425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing Registration Statement filed in connection with proposed business combination between Gelesis and Capstar declared effective by SEC PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Gelesis, announced the appointment of senior financial executive

Ms. Bauerlein brings success in scaling to $300M+ revenue in direct-to-consumer business model and public company execution as Gelesis plans to scale Plenity® to meet growing consumer demand with its upcoming NYSE listing Bauerlein joins Gelesis' board of industry veterans and luminaries who have deep expertise in direct-to-consumer brands, healthcare, and biotechnology Registration Statement filed in connection with proposed business combination between Gelesis and Capstar declared effective by SEC Gelesis, a biotherapeutics company focused on excess weight and metabolic disorders and the maker of Plenity®, announced the appointment of senior financial executive Ali Bauerlein to its Bo

425 - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Subject)

8-K - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

EFFECT - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

S-4/A - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

S-4/A - CAPSTAR SPECIAL PURPOSE ACQUISITION CORP. (0001805087) (Filer)

With the prevalence of fad diets, food shaming and resulting guilt, leading health experts advise against villainizing specific food groups and moving to flexibility and moderation One-of-a-kind, multisensory activation from Plenity® highlights this shifting conversation, rejecting the idea that weight loss is synonymous with deprivation Gelesis, the maker of Plenity®, an FDA-cleared weight management approach, has created an edible billboard in New York City's Astor Place to challenge the idea that people can't eat the foods they love while losing weight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005297/en/Plenity c